Author

F. Chi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. H. Bild· 1 shared A. Nath· 1 shared H. Wu· 1 shared J. A. McQuerry· 1 shared J. Cheng· 1 shared J. Jiao· 1 shared J. Liu· 1 shared J. T. Chang· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. H. Bild

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A 'one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer

F. Chi, J. Liu, S. W. Brady, P. A. Cosgrove, A. Nath, J. A. McQuerry, S. Majumdar, P. J. Moos, J. T. Chang, M. Kahn, A. H. Bild

This study identifies a sequential therapy strategy using HDAC inhibitors to reverse chemotherapy-induced resistance in ER+ breast cancer by targeting cancer stem cell-like traits.

bioRxiv · Mar 12, 2020Cancer Biology

TRIM21 and PHLDA3 Negatively Regulate the Cross-Talk between the PI3K/AKT Pathway and PPP Metabolism

H. Wu, J. Cheng, Y. Huang, X. Zhang, Y. Yu, W. Zhang, M. Wang, L. Zhang, W. Yan, Y. Wu, S. Wu, J. Jiao, L. Tran, F. Chi, P. Jiang

This study shows TRIM21 and PHLDA3 regulate cross-talk between PI3K/AKT signaling and PPP metabolism, with implications for cancer therapy.

bioRxiv · Aug 30, 2019 · PreprintCancer Biology